Rheocarna^® therapy after distal bypass surgery

Area of Science:

• Vascular Surgery
• Peripheral Artery Disease
• Regenerative Medicine

Background:

• Chronic limb-threatening ischemia (CLTI) poses a significant risk for amputation.
• Distal bypass surgery is a revascularization strategy for CLTI.
• Adjuvant therapies are explored to improve outcomes after revascularization.

Purpose of the Study:

• To evaluate the efficacy of Rheocarna® therapy as an adjuvant treatment post-distal bypass surgery.
• To assess the impact of Rheocarna® therapy on skin perfusion pressure (SPP) and continuous walking distance (CWD) in CLTI patients.

Main Methods:

• A prospective study involving 10 patients undergoing distal bypass surgery.
• Rheocarna® therapy administered five times post-operatively.
• Comparison of SPP and CWD before and after Rheocarna® therapy.

Main Results:

• Significant increase in ankle-brachial index (ABI) from 0.62 to 0.936 (p=0.0117).
• Marked improvement in SPP (dorsalis pedis: 71.5 mmHg, planta pedis: 65.0 mmHg) post-therapy (p=0.0020 and p=0.0293, respectively).
• Significant increase in CWD from baseline to 78.5 m (p=0.0039).

Conclusions:

• Rheocarna® therapy significantly enhances SPP and CWD following distal bypass surgery in CLTI patients.
• The findings suggest Rheocarna® is a beneficial adjuvant therapy for improving microcirculation and functional capacity.
• Further research with larger cohorts is warranted to confirm these positive outcomes.